As industrial drone adoption grows, startups are finding bigger opportunities in infrastructure, inspections and field operations.
Updated
May 25, 2026 3:21 PM
An oil pump on a field. PHOTO: UNSPLASH
As drone adoption grows across industrial sectors, more startups are moving beyond hardware sales and into service-based business models. Instead of simply selling drones, companies are increasingly trying to build recurring revenue through inspection, mapping and infrastructure-monitoring services. That shift is shaping ZenaTech’s latest expansion strategy.
ZenaTech is a Vancouver-based startup that develops AI drone and Drone as a Service (DaaS) technologies. The company has signed an offer to acquire an Alberta-based land surveying and geomatics business operating across Western Canada. If completed, the deal would mark ZenaTech’s first land surveying acquisition in Canada and its first major push into the oil and gas sector.
The move gives the startup something more valuable than just another acquisition target. It provides direct access to an industry where drones are already becoming part of everyday operations.
The Alberta surveying company works with oil and gas producers across Alberta, Eastern British Columbia and Saskatchewan. Its services include land surveying, geomatics, mapping and environmental support for infrastructure and energy development projects.
According to ZenaTech, drones are already used in roughly 80 percent of the target company’s existing projects. That matters because it reduces the operational gap between traditional surveying work and AI-powered automation.
Rather than introducing drones into a completely manual workflow, ZenaTech is entering a business where drone-based data collection is already established. The startup says it plans to build on that foundation by integrating more AI-powered capabilities across surveying, mapping, inspections and infrastructure monitoring.
Shaun Passley, Ph.D., CEO of ZenaTech, said: "This proposed acquisition represents an important strategic expansion of our Drone as a Service business into Canada’s oil and gas sector, one of the most significant energy markets in North America. This company brings an established commercial customer base, strong regional expertise, and extensive experience supporting surveying and geomatics projects including for some large producers. We believe there is a significant opportunity to further enhance these services through AI-powered drone technology for surveying, mapping, inspections, and infrastructure monitoring applications, enabling us to establish a core expertise that we can bring to this fast-growing global industry."
The timing is also significant. ZenaTech pointed to estimates showing the global oil and gas drone inspection services market is currently valued at around US$ 2.3 billion and projected to grow at a compound annual growth rate of roughly 28.5 percent.
Much of that growth is being driven by energy companies looking for faster ways to inspect infrastructure, monitor remote sites and reduce manual field operations.
ZenaTech’s broader strategy centers around building a global DaaS network through acquisitions. Instead of creating local operations from scratch, the startup is acquiring existing service businesses with established customers and then layering drone automation and AI systems into those operations.
The company says its DaaS platform offers businesses and government clients subscription-based or on-demand drone services across areas such as inspections, surveying, maintenance, inventory management and precision agriculture.
The larger opportunity for startups in this space may not be drone manufacturing alone. Increasingly, the focus is shifting toward startups that can build scalable drone service networks and integrate them into industries that already rely on large-scale field operations. Oil and gas appear to be one of the next major targets for that expansion.
Keep Reading
METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM
HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.